CABIO(SH:688089) Guoyuan Securities·2025-08-25 08:21Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company reported a total revenue of 307 million yuan in H1 2025, representing a year-on-year increase of 17.60%, and a net profit attributable to the parent company of 108 million yuan, up 59.01% [1] - The growth in revenue is primarily driven by the domestic market, with domestic product sales increasing by 28.66% year-on-year, while overseas product sales grew by 2.38% [2] - The company's gross margin improved to 49.68% in H1 2025, an increase of 7.59 percentage points year-on-year, attributed to enhanced production efficiency and cost optimization [3] - The demand for ARA and DHA, key products of the company, is expected to grow due to the implementation of new national standards for infant formula and the expiration of major patents held by competitors [4] Summary by Sections Financial Performance - In H1 2025, the company achieved a gross profit margin of 49.68%, with a net profit margin of 35.19%, reflecting strong operational efficiency [3] - The company’s sales expenses decreased by 24.32% year-on-year, while management expenses increased by 21.84% due to acquisition-related costs [3] Market Opportunities - The new national standards for infant formula, effective from February 22, 2023, are expected to drive demand for ARA and DHA [4] - The expiration of DSM's major patents in June 2023 presents an opportunity for the company to increase its market share in overseas ARA sales [4] - The Omega-3 market, particularly for DHA, is expanding into functional foods and clinical nutrition, indicating strong demand across various consumer segments [4] Profit Forecast - The company is projected to achieve net profits of 175.21 million yuan, 212.09 million yuan, and 251.48 million yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 41.06%, 21.05%, and 18.57% [5]